Novo Nordisk has launched its Wegovy weight-loss pill in Germany, introducing an oral alternative to the company’s widely used injectable treatment. The move expands options for people seeking medical support for weight management and could broaden access among patients who prefer tablets. The launch comes as demand for obesity treatments continues to grow across Europe. Doctors and health authorities will monitor the pill’s uptake, effectiveness, and safety, while competition in the weight-loss medicines market intensifies in the months ahead.
Published by Banx Network. This article is part of the Banx decentralized media programme, powered by the BXE token on the XRP Ledger.
